Author + information
- Received July 20, 2017
- Revision received September 11, 2017
- Accepted September 12, 2017
- Published online February 26, 2018.
- Christopher T. Nguyen, PhDa,b,
- James Dawkins, DVMc,
- Xiaoming Bi, PhDd,
- Eduardo Marbán, MD, PhDc and
- Debiao Li, PhDa,e,∗ ()
- aBiomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, California
- bCardiovascular Research Center, Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts
- cHeart Institute, Cedars-Sinai Medical Center, Los Angeles, California
- dMR R&D, Siemens Healthcare, Los Angeles, California
- eDepartments of Medicine and Bioengineering, University of California Los Angeles, Los Angeles, California
- ↵∗Address for correspondence:
Dr. Debiao Li, Cedars-Sinai Medical Center, Biomedical Imaging Research Institute, 8700 Beverly Boulevard, Los Angeles, California 90048.
• CDCEXO are RNA-laden nanoparticles that reduce scarring, halt adverse remodeling, and preserve cardiac function in rodents and pigs after MI.
• The therapeutic effects of CDCEXO on myocardial fiber architecture and how it relates to preserved cardiac function and reduced scarring remain unclear.
• After intramyocardial CDCEXO treatment in MI pigs, DT-CMR elucidated myocardial fiber architecture was preserved indicated by the unchanged helix angle transmurality.
• Scar size measured by conventional CMR combined with helix angle transmurality measured by DT-CMR demonstrated significant improvement in the prediction of cardiac function.
• DT-CMR is a powerful technology for myocardial regenerative therapy evaluation revealing unique insight into the myocardium’s microstructure.
The object of the study was to reveal the fiber microstructural response with diffusion tensor cardiac magnetic resonance after intramyocardial exosomes secreted by cardiosphere-derived cells (CDCEXO) in chronic porcine myocardial infarction. Porcine with myocardial infarction underwent intramyocardial delivery of human CDCEXO and placebo in a randomized placebo-controlled study. Four weeks after injection, viability improved in the CDCEXO group, whereas myocardial fiber architecture and cardiac function were preserved. In the placebo group, fiber architecture and cardiac function declined. Myocardial regeneration by CDCEXO is not tumor-like; instead, details of tissue architecture are faithfully preserved, which may foster physiological excitation and contraction.
Dr. Bi is an employee of Siemens Healthcare. Dr. Marbán holds founder’s equity in and serves as unpaid scientific advisor to Capricor Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.
- Received July 20, 2017.
- Revision received September 11, 2017.
- Accepted September 12, 2017.
- 2018 The Authors